Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease

Completed · Phase 2

Conditions studied: Chronic Graft Versus Host Disease

In brief

This randomized trial studies how well discontinuation or continuation of immunosuppressive therapy works in treating participants with chronic graft versus host disease. Continuation of immunosuppressive treatment may prevent graft-versus-host disease worsening.

Key facts

Study ID

NCT03483675

Run by

Fred Hutchinson Cancer Center

People needed

21

Starts

2018-06-06

Expected to finish

2021-03-03

Last updated by the study team

2021-06-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis
• Patients who are on one systemic immunosuppressive agent for chronic GVHD with a plan to withdraw all systemic IST; hydrocortisone or prednisone continued for treatment of adrenal insufficiency is not considered a systemic IST
• No evidence of malignancy at the time of enrollment
• Agree to be evaluated at the transplant center or by local provider every 3 months for 12 months after randomization
• Agreement to be contacted by phone or e-mail for health status evaluation for up to 3 years
• Signed, informed consent

You may not qualify if…

• Inability to comply with study procedures
• Pregancy

Where it is running

• Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.